Lawyers
Corporate partner Krishna Veeraraghavan spoke with Bloomberg Law about deal activity in the health care and biotechnology fields, which have remained steady amid market uncertainty.
“A lot of the innovation has moved to the smaller biotech side and that’s why I think you see a lot more transactions in this space,” says Krishna of deals in these two sectors. “A lot of the smaller biotech companies don’t necessarily have the commercial capability, once their drugs are approved, to get it out and to the patients who need it,” so they turn to larger companies that have the cash and scale needed, he says.
» read the article
